Abstract:Objective: We aimed to assess the relative importance of attributes and the willingness to pay for pharmacological therapies among patients with renal cell carcinoma in China. Methods: Patients with renal cell carcinoma completed a D-efficient-designed, discrete-choice experiment online survey that presented a series of ten trade-off questions and one examining scenario. Based on the literature review and consultations with patients with renal cell carcinoma and clinicians, each question included a pair of hypothetical renal cell carcinoma medication profiles characterized by seven attributes including progression-free survival, objective response rate, medication regimen, fatigue, gastrointestinal reaction, hand-foot syndrome, and monthly out-of-pocket costs. Relative importance and willingness to pay were calculated using coefficients estimated by mixed logit regression in the main analysis. Subgroup analyses were conducted considering the heterogeneity of the participants, based on sex, education level, and income level, using conditional logit regression. Results: The analysis incorporated responses from 182 Chinese respondents. Except for the medication regimen, all attributes were statistically significant. Progression-free survival was the most important attribute, followed by objective response rate, monthly out-of-pocket costs, fatigue, gastrointestinal reaction, and hand-foot syndrome. Patients were willing to pay ￥2010.51 ($298.30), ￥494.93 ($73.43) for 1 unit improvement of progression-free survival, and objective response rate, and￥7558.93 ($1121.50), ￥6927.24 ($1027.78) to avoid experiencing fatigue and gastrointestinal reaction, respectively. Differences in preferences and willingness to pay were found according to patients' gender, income, and education level. Conclusions: In China, patients with renal cell carcinoma preferred medications with better efficacy (objective response rate and progression-free survival) and lower out-of-pocket costs. Heterogeneity can be found in preferences and willingness to pay based on patients' gender, income, and education levels.

Study on the threshold of willingness to pay among end-stage patients in pharmacoeconomic evaluation

Willingness to Pay for Cancer Prevention Versus Treatment in China: Implications for Cost-Effectiveness Threshold.

EE44 Estimating a Cost-Effectiveness Threshold for Health Care Decision-Making in China: Oncology Prevention Versus Treatment

Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year

Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

International comparative study on high-value drugs payment system and its implications for China

Study on Application of Pharmacoeconomic Evaluation in the Price Negotiation System of Patent Drugs

Exploration on the Application of Pharmacoeconomic Drug Economic Evaluation in under the Background of Medical Insurance Payment

A Review of the Method of Performing Pharmacoeconomics Evaluation Using Markov Model and Analysis of Overseas Cases

Incorporating future unrelated medical costs in cost-effectiveness analysis in China

Overview of the Application of Willingness to Pay Approach in Diabetes Mellitus Drug Therapy

Assessment of the quality of pharmacoeconomic evaluation literature in China

Addressing Methodological and Ethical Issues in Practicing Health Economic Evaluation in China.

Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan

A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany’s health technology assessment agency (IQWiG)

Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment

Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: A discrete choice experiment

Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life

Pharmacoeconomic Evaluation Studies in China: Status Quo, Problems and Suggestions

System analysis and evaluation of pharmacoeconomic literatures of cancer published in China

End-of-life Cost and Its Determinants for Cancer Patients in Urban China: a Population-Based Retrospective Study.